Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2012 2
2013 2
2014 2
2015 1
2016 2
2019 2
2020 1
2022 1
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
[Difficulties experienced at work by patients with multiple sclerosis].
Ongagna JC, Passadori A, Pinelli J, Isner-Horobeti ME, Zaenker C, De Seze J. Ongagna JC, et al. Among authors: zaenker c. Rev Neurol (Paris). 2015 Nov;171(11):782-6. doi: 10.1016/j.neurol.2015.06.007. Epub 2015 Sep 3. Rev Neurol (Paris). 2015. PMID: 26343923 French.
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.
Papeix C, Castelnovo G, Leray E, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group. Papeix C, et al. Neurol Ther. 2022 Jun;11(2):633-658. doi: 10.1007/s40120-022-00334-y. Epub 2022 Feb 11. Neurol Ther. 2022. PMID: 35147904 Free PMC article.
Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
Donzé C, Papeix C, Lebrun-Frenay C; French Group for Recommendations in Multiple Sclerosis (France4MS); Société francophone de la sclérose en plaques (SFSEP); SPILF; Co-chairs; Supervision of the readers; Readers; Rating group; Reading group. Donzé C, et al. Rev Neurol (Paris). 2020 Dec;176(10):804-822. doi: 10.1016/j.neurol.2020.02.011. Epub 2020 Sep 5. Rev Neurol (Paris). 2020. PMID: 32900473
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators. Cohen M, et al. JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240. JAMA Neurol. 2014. PMID: 24566807 Clinical Trial.
Reduction of the washout time between natalizumab and fingolimod.
de Seze J, Ongagna JC, Collongues N, Zaenker C, Courtois S, Fleury M, Benoilid A, Chanson JB, Blanc F; Alsacep Network. de Seze J, et al. Among authors: zaenker c. Mult Scler. 2013 Aug;19(9):1248. doi: 10.1177/1352458513490551. Epub 2013 May 30. Mult Scler. 2013. PMID: 23722322 No abstract available.
15 results